Healthcare provider profile · identity verified

Eva A Waite, MD

Internal Medicine · NEW YORK, NY · NPI 1902838030

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	425	134
Amlodipine Besylate	Amlodipine Besylate	238	81
Fluticasone Propionate	Fluticasone Propionate	191	53
Omeprazole	Omeprazole	185	54
Gabapentin	Gabapentin	184	40
Famotidine	Famotidine	180	45
Losartan Potassium	Losartan Potassium	176	57
Lisinopril	Lisinopril	170	56
Metoprolol Succinate	Metoprolol Succinate	164	44
Levothyroxine Sodium	Levothyroxine Sodium	159	39
Albuterol Sulfate Hfa	Albuterol Sulfate	153	40
Rosuvastatin Calcium	Rosuvastatin Calcium	113	33
Diclofenac Sodium	Diclofenac Sodium	112	23
Metformin Hcl Er	Metformin Hcl	107	27
Metformin Hcl	Metformin Hcl	105	35
Jardiance	Empagliflozin	102	25
Furosemide	Furosemide	94	25
Pantoprazole Sodium	Pantoprazole Sodium	89	28
Ammonium Lactate	Ammonium Lactate	85	19
Meclizine Hcl	Meclizine Hcl	68	18
Ozempic	Semaglutide	68	16
Hydrochlorothiazide	Hydrochlorothiazide	64	24
Trulicity	Dulaglutide	63	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	62	22
Nifedipine Er	Nifedipine	61	28
Sertraline Hcl	Sertraline Hcl	59	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	59	15
Alcohol Prep Pads	Alcohol Antiseptic Pads	58	15
Montelukast Sodium	Montelukast Sodium	58	12
Carvedilol	Carvedilol	56	17
Hydrocortisone	Hydrocortisone	48	18
Ezetimibe	Ezetimibe	46	16
Eliquis	Apixaban	45	suppressed
Alendronate Sodium	Alendronate Sodium	44	12
Ketoconazole	Ketoconazole	42	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	41	13
Trazodone Hcl	Trazodone Hcl	41	suppressed
Chlorthalidone	Chlorthalidone	40	15
Januvia	Sitagliptin Phosphate	40	suppressed
Mounjaro	Tirzepatide	39	suppressed
Duloxetine Hcl	Duloxetine Hcl	38	12
Pravastatin Sodium	Pravastatin Sodium	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	37	suppressed
Symbicort	Budesonide/Formoterol Fumarate	36	12
Valacyclovir	Valacyclovir Hcl	36	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	36	12
Tramadol Hcl	Tramadol Hcl	35	suppressed
Azelastine Hcl	Azelastine Hcl	34	suppressed
Valsartan	Valsartan	34	11
Ibuprofen	Ibuprofen	32	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	11
Naproxen	Naproxen	32	suppressed
Pregabalin	Pregabalin	32	suppressed
Finasteride	Finasteride	30	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	30	suppressed
Clopidogrel	Clopidogrel Bisulfate	29	suppressed
Propranolol Hcl Er	Propranolol Hcl	29	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	27	suppressed
Spironolactone	Spironolactone	27	11
Allopurinol	Allopurinol	26	suppressed
Baclofen	Baclofen	26	suppressed
Clonidine Hcl	Clonidine Hcl	26	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	26	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	25	suppressed
Mirtazapine	Mirtazapine	23	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Incruse Ellipta	Umeclidinium Bromide	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Clotrimazole	Clotrimazole	19	suppressed
Prednisone	Prednisone	19	13
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Folic Acid	Folic Acid	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Theophylline Er	Theophylline Anhydrous	17	suppressed
Tradjenta	Linagliptin	17	suppressed
Ursodiol	Ursodiol	17	suppressed
Atenolol	Atenolol	16	suppressed
Lidocaine	Lidocaine	16	suppressed
Mometasone Furoate	Mometasone Furoate	16	suppressed
Loperamide	Loperamide Hcl	15	suppressed
Simvastatin	Simvastatin	15	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	15	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Linzess	Linaclotide	14	suppressed
Nyamyc	Nystatin	14	suppressed
Oxycodone Hcl	Oxycodone Hcl	14	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Clonidine	Clonidine	13	suppressed
Fludrocortisone Acetate	Fludrocortisone Acetate	13	suppressed
Novolog Flexpen	Insulin Aspart	13	suppressed
Nystatin	Nystatin	13	suppressed
Primidone	Primidone	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Memantine Hcl	Memantine Hcl	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Single Use Swab	Alcohol Antiseptic Pads	12	suppressed
Tramadol Hcl Er	Tramadol Hcl	12	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Letrozole	Letrozole	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lyrica	Pregabalin	11	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Ultra-Fine Original Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error